טוען...
Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
Aims: Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years. The aim of this study was to investigate the in vitro effects of PIO on normal urothelial transitional epithelium (NUTE) c...
שמור ב:
| הוצא לאור ב: | Int J Med Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ivyspring International Publisher
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5820852/ https://ncbi.nlm.nih.gov/pubmed/29483814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijms.22408 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|